Surveillance of invasive bacterial disease in Alaska, 2008 by National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Division of Division of Preparedness and Emerging Infections. Arctic Investigations Program.
  
 
 
 
 
 
 
Surveillance of Invasive Bacterial Disease in Alaska, 2008 
 
 
 
 
 
 
Arctic Investigations Program 
National Center for Emerging & Zoonotic Infectious Diseases 
Centers for Disease Control and Prevention 
4055 Tudor Centre Dr. 
Anchorage, AK  99508 
(907) 729-3400 
ncidaip@cdc.gov
 Surveillance of Invasive Bacterial Disease in Alaska, 2008                                                    2         
 Surveillance of Invasive Bacterial Disease in Alaska, 2008                                                    3         
Alaska Statewide Invasive Bacterial Disease 
 
Table of Contents 
 
           Page 
 
Summary                4 
 
Introduction                5 
 
Invasive Pneumococcal Disease             6 
 
Invasive Haemophilus influenzae           16 
  
Invasive Neisseria meningitidis           21 
 
Invasive Group A Streptococcus           23 
 
Invasive Group B Streptococcus           27 
 
References              31 
 
Appendix              32 
 Surveillance of Invasive Bacterial Disease in Alaska, 2008                                                    4         
Summary 
 
The Centers for Disease Control and Prevention's Arctic Investigations Program (AIP) in Anchorage, 
Alaska, maintains a statewide surveillance system for invasive diseases caused by Streptococcus 
pneumoniae, Haemophilus influenzae, Neisseria meningitidis, and groups A and B streptococci.  
Laboratories throughout the state are requested to send to AIP any isolates of these organisms recovered 
from a blood culture, CSF, or other normally sterile site in an Alaska resident. Isolate identification is 
confirmed and, when appropriate, serotyped and tested for antimicrobial susceptibility.  The objectives 
of this system are to provide information on disease rates within the state, monitor the emergence of 
antimicrobial resistance, and to monitor the effectiveness of implemented vaccine programs, such as the 
23-valent pneumococcal polysaccharide vaccine, the pneumococcal conjugate vaccine and Haemophilus 
influenzae type b vaccines. 
 
Figure 1:  Invasive Bacterial Disease Surveillance Regions – Alaska, 2008 
In 2008, the total numbers of cases of invasive disease caused by these organisms reported to AIP were 
148 S. pneumoniae, 21 H. influenzae, 5 N. meningitidis, 38 group A Streptococci (GAS) and 28 group B 
Streptococci (GBS).  Alaska Native people had higher rates of disease than non-Native people for all 
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surveillance organisms except Neisseria meningitidis.  Rates of invasive pneumococcal disease were 
highest in the YK Delta.  Rates for each organism by region are presented in the following table. 
 
Table 1:  Surveillance Organisms Reported by Region – Alaska, 2008 
 
Region 
S. pneumoniae 
n (rate*) 
H. influenzae 
n (rate*) 
N. meningitidis 
n (rate*) 
GAS 
n (rate*) 
GBS 
n (rate*) 
Anchorage 74 (16.4) 9 (2) 4 (0.9) 25 (5.5) 20 (4.4) 
Arctic Slope 3 (52.3) 1 (17.4) 0 (0) 0 (0) 0 (0) 
Bristol Bay 2 (28.6) 0 (0) 0 (0) 0 (0) 0 (0) 
Interior 23 (22.2) 3 (2.9) 1 (1) 1 (1) 4 (3.9) 
Kotzebue 3 (37.1) 0 (0) 0 (0) 3 (37.1) 0 (0) 
Norton Sound 3 (31.6) 1 (10.5) 0 (0) 0 (0) 0 (0) 
Southeast 16 (23.1) 2 (2.9) 0 (0) 3 (4.3) 3 (4.3) 
YK Delta 24 (96.4) 5 (20.1) 0 (0) 6 (24.1) 1 (4) 
Total 148 (21.8) 21 (3.1) 5 (0.7) 38 (5.6) 28 (4.1) 
*Cases per 100,000 population 
 
Introduction 
 
AIP conducts statewide surveillance of invasive Streptococcus pneumoniae, Haemophilus influenzae, 
Neisseria meningitidis, and groups A and B Streptococcus.  This program is part of a passive, 
laboratory-based surveillance system in which laboratories from all hospitals throughout the state are 
encouraged to participate.  The population included in the AIP surveillance is the State of Alaska, which 
totaled 679,720 persons in 2008 [1].  Case detection occurs year-round as participating laboratories send 
isolates recovered from sterile sites to the AIP laboratory in Anchorage, accompanied by basic 
demographic and clinical information on the cases.  Materials and forms for isolate shipment and data 
collection are provided to each laboratory by AIP.  At year-end, AIP asks that each laboratory review 
their records and provide information on any cases that may have been overlooked.  In 2008, 23 
laboratories in Alaska participated in the invasive disease surveillance system, either by sending isolates 
to the AIP laboratory throughout the year, conducting year-end record reviews, or both.  Beginning in 
January, 2007, invasive S. pneumoniae, GAS and GBS became reportable conditions to the State of 
Alaska Division of Public Health (DPH).  Reports of cases of disease caused by these organisms, along 
with cases of invasive H. influenzae and N. meningitidis which were previously reportable, are shared 
between AIP and DPH. 
 
AIP defines a case of invasive S. pneumoniae, H. influenzae, N. meningitidis, GAS or GBS as an isolate 
of the bacteria from a normally sterile site, including blood, cerebrospinal fluid, pleural fluid, peritoneal 
fluid or joint fluid that has been taken from a resident of Alaska.  In addition, for GAS, isolates are 
requested from deep tissue infections such as might be collected from surgical debridement of cases of 
necrotizing fasciitis. 
 
 Surveillance of Invasive Bacterial Disease in Alaska, 2008                                                    6         
Invasive Pneumococcal Disease 
 
Overall Incidence 
 
A total of 138 pneumococcal isolates were received at AIP in 2008.  An additional 3 cases were detected 
through year-end follow up with participating laboratories, 6 cases through shared surveillance with the 
State DPH and one case through on-site personnel review of medical records for a total of 148 cases of 
invasive pneumococcal disease.  The overall rate for invasive pneumococcal disease in 2008 was 21.8 
cases per 100,000 persons per year.  Alaska rates for 2008 were higher than the Active Bacterial Core 
Surveillance (ABCs) 2008 national projected rate of 14.5/100,000 [2].  ABCs is a surveillance system 
operated in 10 states which covers a population of over 39 million persons. 
 
Seasonality 
 
Invasive Streptococcus pneumoniae cases were identified in each month of 2008.  The largest number of 
cases was reported in April. 
 
 
 
 
Race 
 
In 2008, the state population was comprised of 19.8% Alaska Native people (Alaska Natives 134,633, 
non-Natives 545,087) [1].  Of all reported S. pneumoniae cases in 2008, 51% occurred among Alaska 
Native people for a total of 76 cases; the age-adjusted rate was 54.4/100,000 persons per year.  Seventy-
two cases occurred among the non-Native population with an age-adjusted rate of 11.8/100,000 persons 
per year.  The rate ratio of age-adjusted rates of S. pneumoniae disease for the Alaska Native population 
compared with the non-Native population in 2008 was 4.6. 
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Figure 2:  Invasive Pneumococcal Disease, by 
Month of Culture - Alaska, 2008
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Table 2:  Invasive Streptococcus pneumoniae Cases by Race – Alaska, 2008  
Race 
Cases 
n (%) 
Age Adjusted 
Rate* % Male 
Deaths 
n (%) 
Alaska Native 76 (51) 54.4 46 7 (9.2) 
Non-Native 72 (49) 11.8 54 6 (8.3) 
Total 148  50 13 (8.8) 
*Cases per 100,000 per percent distribution of Alaska 2000 population 
 
Region 
 
The highest percentage (50%) of invasive pneumococcal disease cases occurred in the Anchorage area 
in 2008.  Rates of disease, however, were highest in the YK Delta (96.4/100,000 persons per year). 
 
 
 
Age 
 
Cases occurred in all age groups in 2008 ranging from 4 months to 101 years with a median age of 46 
years.  Overall, the highest rates of disease occurred in children less than 2 years old. 
   
When stratified by age and race, the highest rates of disease in 2008 occurred in Alaska Native children 
less than 2 years old (210.7/100,000 persons per year).  
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Figure 3:  Invasive Pneumococcal Disease, Cases 
& Rates by Region - Alaska, 2008
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Since the initiation of a pneumococcal conjugate vaccine program in 2001, overall rates of invasive 
disease have declined dramatically in children less than 2 years of age [3].  In 2000, overall yearly rates 
of pneumococcal disease in children less than 2 years were 191.2/100,000, dropping to a low of 
67.9/100,000 in 2002 and then increasing to 142.2/100,000 in 2006.  In 2008, the rate of invasive 
pneumococcal disease in children less than 2 years declined to 65.6/100,000 which is the lowest rate 
observed in this age group since vaccine introduction. 
 
 
 
Although pneumococcal disease rates dropped initially in AK Native and non-Native children less than 
2 years of age after 2000, the rates of disease in AK Native children less than 2 years trended upward 
from a low of 93.6/100,000 in 2001 to 335.9/100,000 in 2006.  This increase in rates is due primarily to 
disease caused by serotypes not contained in the pneumococcal conjugate vaccine [4,5].  Although the 
rate of invasive pneumococcal disease in AK Native children less than 2 years in 2008 was 
210.7/100,000, this is 34 times the rate of disease seen in non-Native children.  Rates of invasive disease 
in non-Native children less than 2 years declined during the same time period reaching 26.8/100,000 in 
2005, increasing to 64.4/100,000 in 2007 and declining in 2008 to 6.2/100,000. 
0
50
100
150
200
250
0
5
10
15
20
25
30
35
40
<2 2-4 5-18 19-54 55-64 65+
R
at
e 
pe
r 
10
0,
00
0
N
u
m
be
r 
o
f C
as
es
Age (yrs)
Figure 4: Invasive Pneumococcal Disease, Cases 
& Rates by Age Group & Race - Alaska, 2008
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Group - Alaska, 2000-2008
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Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each 
patient’s individual medical record associated with the invasive bacterial illness.  In cases with multiple 
discharge diagnoses, the most serious diagnosis related to the pneumococcal infection was recorded as 
the primary clinical presentation.  Pneumonia with bacteremia was the most common primary clinical 
presentation in 2008 (71%) followed by bacteremia (13%).  Nineteen cases had a secondary 
pneumococcal-related diagnosis in 2008 – 13 pneumonia, 3 cellulitis, 1 endocarditis, 1 empyema and 1 
septic arthritis. 
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Figure 6: Invasive Pneumococcal Disease in 
Alaska Natives, by Age Group - Alaska, 2000-2008
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Figure 7: Invasive Pneumococcal Disease in Non-
Natives, by Age Group - Alaska, 2000-2008
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In 2008, blood was the most common source of a positive culture which was used to identify 138 (95%) 
of 146 cases.  Cerebrospinal fluid was the positive site for 4 (3%) cases, 3 cases were identified from 
pleural fluid and 1 case from an abscess. 
 
Mortality 
 
In 2008, the overall case fatality ratio for S. pneumoniae in Alaska was 8.8% (13 deaths out of 148 cases 
for which outcomes were known).  The case fatality ratio for AK Natives was higher than non-Natives; 
9.2% (7 deaths) and 8.3% (6 deaths), respectively.  Although the majority of deaths occurred in the 19-
54 age category (6 deaths), the highest case fatality ratio occurred in the 55-64 age category; 15.8% (5 
deaths). 
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Figure 8: Primary Clinical Presentations of 
Invasive Pneumococcal Disease - Alaska, 2008
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Figure 9: Invasive Pneumococcal Deaths & Case 
Fatality Ratios by Age Group - Alaska, 2008
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Serotype 
 
Serotyping of invasive pneumococcal isolates is performed at AIP using internationally standardized 
methods.  Serotype identification is based on the organism’s polysaccharide capsule which is a principal 
virulence factor for pneumococci.  This information provides a way to categorize organisms and to 
determine if the infection was due to a type that could be prevented by use of one of the available 
pneumococcal vaccines.  Serotyping was performed on all of the S. pneumoniae cases for which an 
isolate was available. 
 
Table 3:  Invasive Pneumococcal Serotype Distribution by Race and Age Group – Alaska, 2008 
  Alaska Native Non-Native 
Serotype Total n (%) <2 2-18 19-64 65+ <2 2-18 19-64 65+ 
03 3 (2) 1 - - - - 1 1 - 
06A 2 (1) - - 1 - - - - 1 
06C 2 (1) - - 1 - - - 1 - 
07C 1 (<1) - - - - - - 1 - 
07F 29 (22) 2 3 4 - 1 3 13 3 
08 7 (5) - - 4 - - 1 2 - 
09N 1 (<1) - - - - - - - 1 
09V 1 (<1) - - - - - - 1 - 
10A 3 (2) - - 1 - - - - 2 
10F 2 (1) - - - - - - - 2 
11A 2 (1) - - - - - - 1 1 
12F 11 (8) - - 7 1 - - 3 - 
15A 4 (3) 1 - 1 - - - 2 - 
15B 2 (1) - - 1 - - - 1 - 
16F 4 (3) - - 1 1 - - - 2 
19A 28 (21) 7 4 4 2 - 1 8 2 
19F 2 (1) 1 - - 1 - - - - 
20 8 (6) - - 6 1 - - 1 - 
22F 11 (8) - 1 3 - - - 5 2 
23A 1 (<1) - - 1 - - - - - 
23B 4 (3) 1 - - - - 1 1 1 
31 1 (<1) - - 1 - - - - - 
33F 3 (2) - 1 1 - - - - 1 
35B 3 (2) 1 - 1 1 - - - - 
Total 135 14 9 38 7 1 7 41 18 
 
In 2008, the most common pneumococcal serotypes were 7F (29 isolates, 22%) and 19A (28 isolates, 
21%).  From 1986 through 2001, serotype 14 was the most common invasive pneumococcal serotype 
ranging from 7.4% to 23.5% of isolates.  Following introduction in 2001 of the pneumococcal conjugate 
vaccine which includes serotype 14, the proportion of serotype 14 isolates dropped to 1.5% of serotyped 
isolates in 2006 and did not cause any invasive pneumococcal disease in 2008.  However, disease caused 
by serotypes 7F and 19A, which are not included in the conjugate vaccine, has increased.  Prior to 2005, 
yearly numbers of cases of serotype 7F disease and the proportion of total isolates have ranged from 1 to 
10 and 0.9% to 9.3%, respectively.  Although the majority (62.5%) of serotype 7F disease occurred in 
AK Natives during 2005, it was more evenly distributed between AK Native people (48%) and non-
Natives (52%) in 2006. In 2007, the proportion of serotype 7F disease increased in non-Natives (57%) 
versus AK Natives (43%) and reached 69% versus 31%, respectively, in 2008.  The majority (66%) of 
serotype 7F cases occurred in the Anchorage area in 2008.   
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Table 4:  Invasive Pneumococcal Serotype Distribution by Region – Alaska, 2008 
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03 2 - - - - 1 - - 
06A 1 - - 1 - - - - 
06C 1 - - 1 - - - - 
07C 1 - - - - - - - 
07F 19 - - 5 - - 3 2 
08 3 - - - 1 1 2 - 
09N 1 - - - - - - - 
09V 1 - - - - - - - 
10A 1 - - - - - 1 1 
10F 2 - - - - - - - 
11A 1 - - 1 - - - - 
12F 5 - 1 - - - - 5 
15A 2 - - 1 - - - 1 
15B 1 - - - - - 1 - 
16F 2 - - - - - 2 - 
19A 8 2 1 8 - 1 2 6 
19F 1 - - - - - 1 - 
20 5 - - 3 - - - - 
22F 7 1 - - - - 1 2 
23A 
- - - - - - - 1 
23B 2 - - 1 - - - 1 
31 1 - - - - - - - 
33F 2 - - - - - - 1 
35B 1 - - - 1 - - 1 
Total 70 3 2 21 2 3 13 21 
 
Vaccine Serotypes 
 
Two vaccine types were licensed for prevention of pneumococcal disease in 2008.  In 2001, the 
pneumococcal conjugate vaccine (PCV7) was included in the Alaska childhood vaccination schedule.  
This vaccine provides protection against the 7 most common pneumococcal serotypes causing invasive 
disease among children (types 4, 6B, 9V, 14, 18C, 19F, 23F).  The table below shows the proportion of 
invasive infections from 2008 that were due to serotypes found in the PCV7 vaccine.  There was one 
case of pneumococcal disease caused by a serotype (19F) contained in the PCV7 vaccine in a child less 
than 5 years of age, the age group for which the vaccine is recommended, however, the child had not 
received any doses of vaccine. 
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Table 5:  Proportion of Invasive Isolates Contained in the PCV7 Vaccine by Age Group and Race 
– Alaska, 2008 
Age (yrs) Alaska Native (%) Non-Native (%) Total (%) 
<2 1 (7%) of 14 0 (0%) of 1 1 (7%) of 15 
2-4 0 (0%) of 4 0 (0%) of 4 0 (0%) of 8 
5+ 1 (2%) of 49 1 (2%) of 59 2 (2%) of 108 
Total 2 (3%) of 67 1 (2%) of 64 3 (2%) of 131 
 
For the year covered by this report, the 23-valent polysaccharide vaccine (Ps23V) was recommended in 
Alaska for all persons 55 years and older, and for persons over age 2 who are at higher risk for 
pneumococcal disease.  Revaccination was recommended after 6 years [6].  In 2008, for persons 55 
years and older, 31 (74%) of 42 cases serotyped were potentially vaccine preventable invasive 
pneumococcal illnesses.  
 
Vaccine Failures 
 
A PCV7 vaccine failure is defined as invasive pneumococcal disease caused by a serotype contained in 
the PCV7 vaccine in a child less than five years old who has had at least two doses of vaccine.  There 
were no vaccine failures in 2008. 
 
Potentially Preventable Deaths 
 
In 2008, pneumococcal vaccine status was known for 96 (66%) of the 146 cases; 59 cases (40%) did 
receive a pneumococcal vaccine prior to illness and 37 cases (25%) had no record of a pneumococcal 
vaccine. 
 
Table 6:  Potentially Vaccine Preventable Invasive Pneumococcal Deaths – Alaska, 2008 
Serotypes < 2 years 2-4 5-18 19-54 55-64 65+ Total 
PCV7 0 0 0 1 (17%) 0 0 1 (8%) 
Ps23V 0 0 1 (100%) 3 (50%) 2 (67%) 3 (100%) 9 (69%) 
Non-Vaccine 0 0 0 1 (17%) 0 0 1 (8%) 
Unknown 0 0 0 1 (17%) 1 (33%) 0 2 (15%) 
Total 0 0 1 6 3 3 13 
 
Overall, 69% of all pneumococcal-related mortality in 2008 was potentially preventable with the use of 
the 23-valent polysaccharide vaccine in persons over 2 years old; 16% of deaths were due to disease 
caused by serotypes not contained in the 23-valent vaccine.   
 
Nine of the 13 deaths in 2008 from invasive S. pneumoniae occurred from serotypes contained within 
the Ps23V vaccine; 5 of the deaths were in individuals eligible for the vaccine.  Of those five deaths, two 
occurred in vaccinated individuals; time since vaccination for each was 3 years and 12 years. 
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Table 7:  Invasive Pneumococcal Disease, Serotypes of Fatal Cases – Alaska, 2009 
Serotype 
Deaths  
n (%) 
Serotype 
Frequency (n) 
03* 1 (33%) 3 
08* 1 (14%) 7 
09V†* 1 (100%) 1 
10A* 1 (33%) 3 
15A 1 (25%) 4 
20* 3 (38%) 8 
22F* 2 (18%) 11 
33F* 1 (33%) 3 
†Serotypes contained in the 7-valent conjugate vaccine 
*Serotypes contained in the 23-valent polysaccharide vaccine 
 
Associated Medical Conditions 
 
The presence of one or more associated medical conditions was reported in 86% of invasive 
pneumococcal cases in 2008.  Cigarette smoking was the most prevalent risk factor observed in adults 
followed by alcohol abuse and chronic lung disease. 
 
Table 8:  Associated Medical Conditions Identified in Invasive Pneumococcal Cases – Alaska, 
2008* 
Medical Condition/Risk 
Factor 
Adult Cases (≥ 18 years) 
n=112, Cases (%) 
Cigarette smoking 53 (47) 
Alcohol abuse 40 (36) 
Chronic lung disease 28 (25) 
Diabetes 17 (15) 
Immunosuppressive treatment 5 (5) 
Injection drug use 0 (0) 
Asplenia 0 (0) 
*More than one risk factor was identified in several cases 
 
Antibiotic Resistance 
 
Susceptibility testing was performed on all isolates received in 2008.  Results of the testing are 
presented in the following table. 
 
Table 9:  Antibiotic Resistance in Invasive Streptococcus pneumoniae Isolates – Alaska, 2008 
Antibiotic Susceptible Intermediate Resistant I + R Total Tested 
Penicillin 106 (79%) 25 (19%) 4 (3%) 29 (22%) 135 
TMP-sulfa 100 (74%) 9 (7%) 26 (19%) 35 (26%) 135 
Erythromycin 114 (84%) 0 (0%) 21 (16%) 21 (16%) 135 
Ceftriaxone 130 (96%) 3 (2%) 2 (2%) 5 (3%) 135 
Tetracycline 131 (97%) 0 (0%) 4 (3%) 4 (3%) 135 
Chloramphenicol 133 (98%) 0 (0%) 2 (1%) 2 (1%) 135 
Rifampin 135 (100%) 0 (0%) 0 (0%) 0 (0%) 135 
Vancomycin 133 (98%) 0 (0%) 2 (2%) 2 (2%) 135 
Levofloxacin 131 (97%) 0 (0%) 4 (3%) 4 (3%) 135 
Clindamycin 134 (99%) 0 (0%) 1 (1%) 1 (1%) 135 
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Cut points from the Minimum Inhibitory Concentration (MIC) Interpretive Standards were used to 
determine if an isolate was ‘susceptible’, ‘intermediate’, or ‘resistant’ to the antibiotic being tested [7].  
The MIC Interpretive Standards definitions of ‘susceptible’, ‘intermediate’, and ‘resistant’ can be found 
in the Appendix. 
 
Serotypes found in the PCV7 vaccine are more likely to be non-susceptible to penicillin and 
erythromycin than non-vaccine serotypes.  One potential benefit of the use of this vaccine was an 
anticipated decline in antibiotic resistance among circulating pneumococci.  Following the initiation of 
the PCV7 vaccine in 2001, antibiotic resistance among invasive pneumococci dropped.  During 2003, 
TMP-sulfa and penicillin resistance increased, however, both decreased in 2004 to similar levels of 
resistance seen in 2002 and remained at those levels until 2008 when both show an increase.  After 
steadily declining from 2000 to a low of 4% in 2004, erythromycin resistance has increased to 16% of 
tested isolates in 2008. 
 
 
               *Pen-FR = fully resistant, Pen-NS = non-susceptible 
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Figure 10: Trends in Antibiotic Resistance Among 
Invasive Pneumococcal Isolates - Alaska, 1989 - 2008
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Invasive Haemophilus influenzae 
 
Overall Incidence 
 
In 2008, there were 21 cases of invasive Haemophilus influenzae in Alaska, for a statewide rate of 
3.1/100,000 persons per year.  This rate is higher than the national projected rate of 1.55/100,000 
persons per year [7].  There were three deaths caused by H. influenzae in 2008 for a case fatality ratio of 
14%.   
 
Seasonality 
 
 
Cases of invasive H. influenzae occurred throughout 2008; however, due to the small number of cases, 
trends in seasonality cannot be determined. 
 
Region 
 
The highest rates of disease caused by invasive H. influenzae cases in 2008 were in YK Delta, 
20.1/100,000 (5 cases), and the Arctic Slope, 17.4/100,000 (1 case).  The largest number of cases 
occurred in the Anchorage area (9 cases), but the rate was much lower (2/100,000). 
 
0
1
2
3
4
5
N
u
m
be
r 
o
f C
a
se
s
Month of Culture
Figure 11: Haemophilus influenzae Disease by 
Month of Culture - Alaska, 2008
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Race 
 
Table 10:  Invasive Haemophilus influenzae Cases by Race – Alaska, 2008 
Race 
Cases      
n (%) 
Age Adjusted 
Rate* % Male 
Deaths  
n (%) 
Alaska Native 10 (48%) 6.6 60 0 (0%) 
Non-Native 11 (52%) 1.6 64 3 (27%) 
Total 21  62 3 (14%) 
*Cases per 100,000 per percent distribution of Alaska 2000 population 
 
In 2008, 52% of the cases occurred in non-Natives.  Age-adjusted rates were calculated for Alaska 
Natives and non-Natives.  The age-adjusted rate ratio of H. influenzae disease for the Alaska Native 
population compared with the non-Native population in 2008 was 4.1. 
 
Age 
 
H. influenzae cases ranged in age from newborn to 93 years of age in 2008 (median 54.4 years).  
Overall, the highest rates of disease occurred in children less than 2 years old and adults 65 and older. 
 
Rates of disease in Alaska Native versus non-Native populations by age group were variable; overall 
numbers of cases and rates by race and age group are presented in Figure 14.  The highest rates of 
disease occurred in Alaska Native children less than two years of age, 45.2/100,000 persons per year and 
Alaska Native adults 65 years and older, 25.1/100,000 persons per year.   
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Figure 12: Invasive Haemophilus influenzae, 
Cases & Rates by Region - Alaska, 2008
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Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each 
patient’s individual medical record associated with the invasive bacterial illness.  For cases with more 
than one diagnosis, the most serious H. influenzae-related diagnosis was recorded as the primary clinical 
presentation.  In 2008, pneumonia with bacteremia was the most common presentation (43% of cases).  
 
H. influenzae was isolated from 17 (81%) blood samples, 2 (10%) cerebrospinal fluid samples, 1 (5%) 
pleural fluid sample, and 1 (5%) joint fluid sample.  
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Figure 13: Invasive Haemophilus influenzae by 
Age Group - Alaska, 2008
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Figure 14: Invasive Haemophilus influenzae, Cases & 
Rates by Age Group & Race - Alaska, 2008
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Table 11:  Primary Clinical Presentation of Invasive Haemophilus influenzae - Alaska, 2008 
Primary Presentation n (%) 
Pneumonia* 9 (43%) 
Bacteremia 7 (33%) 
Meningitis 2 (10%) 
Septic Arthritis 2 (10%) 
Empyema 1 (5%) 
Total 21 
*with bacteremia 
 
Serotypes 
 
All isolates received at AIP are serotyped; 20 of the 21 cases in 2008 had isolates and were serotyped.  
The bacterial capsule is the basis for serotyping and is the primary virulence factor.  Serotype b has been 
the most common serotype in the past, but its prevalence has decreased with use of the childhood Hib 
vaccine.  Surveillance of serotypes is important for monitoring vaccine effectiveness and emergence of 
non-vaccine serotypes. 
 
Table 12:  Serotypes of Invasive Haemophilus influenzae Cases by Race – Alaska, 2008 
  Alaska Native Non-Native 
Serotype Total n (%) <2 2-18 19-64 65+ <2 2-18 19-64 65+ 
a 2 0 1 0 0 1 0 0 0 
b 3 2 0 1 0 0 0 0 0 
e 1 0 0 1 0 0 0 0 0 
f 1 0 0 0 0 1 0 0 0 
NT* 13 1 0 2 2 2 0 2 4 
Total 20 3 1 4 2 4 0 2 4 
*Non-typable 
 
Hib 
 
In recent years, the prevalence of H. influenzae type b has declined due to increased use of a childhood 
vaccine against this serotype.  Three cases of Hib occurred in 2008; two in unvaccinated children under 
the age of 2 and one in a 43 year old adult. 
 
Antibiotic Resistance 
 
Nineteen Haemophilus influenzae isolates received at AIP were tested for susceptibility to 
chloramphenicol, ceftriaxone and TMP/sulfa.  All 19 isolates were susceptible to ceftriaxone; one isolate 
was fully resistant to chloramphenicol; 2 were fully resistant to TMP/sulfa 3 had intermediate resistance 
and 14 were susceptible. 
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Table 13:  Summary of Invasive Haemophilus influenzae Case Characteristics, Alaska, 2008 
Sex Age (Yrs) Race Residence 
Site of 
Isolation 
Clinical 
Presentation(s) Serotype* 
Associated Medical 
Conditions Survived 
M Newborn Non-Native Other Blood Bacteremia NT None Yes 
F Newborn AK Native Other Blood Bacteremia NT None Yes 
M 10 days Non-Native Anchorage Blood Bacteremia NT None Yes  
M 0.2 AK Native Other CSF Meningitis b None Yes  
M 0.5 Non-Native Other CSF Meningitis f None Yes 
M 0.6 Non-Native Anchorage Blood Septic arthritis a None Yes  
F 1.2 AK Native Other Blood Pneumonia b None Yes 
M 2.4 AK Native Other Blood Pneumonia a Chronic lung disease Yes 
M 43.5 AK Native Anchorage Blood Pneumonia b Smoking, alcohol abuse Yes  
M 45.5 AK Native Other Blood Pneumonia e 
Smoking, 
immunosuppressive 
treatment 
Yes 
 
M 54.4 AK Native Anchorage Blood Bacteremia NT Smoking Yes  
M 56.2 Non-Native Anchorage Joint fluid Septic arthritis Unknown Immunosuppressive treatment Yes 
 
F 62.3 AK Native Other Blood Pneumonia NT Chronic lung disease Yes  
M 63.5 Non-Native Anchorage Blood Pneumonia NT Diabetes No  
F 64.2 Non-Native Anchorage Pleural fluid 
Empyema, 
pneumonia NT 
Smoking, chronic lung 
disease, diabetes No 
 
M 75.7 AK Native Other Blood Pneumonia NT Chronic lung disease Yes  
F 77.4 Non-Native Anchorage Blood Bacteremia NT None Yes  
M 80.1 Non-Native Other Blood Pneumonia NT Diabetes Yes  
F 85.7 Non-Native Anchorage Blood Pneumonia NT None Yes  
F 92.4 Non-Native Other Blood Bacteremia NT None No  
F 92.7 AK Native Other Blood Bacteremia NT None Yes  
*NT = non-typeable 
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Invasive Neisseria meningitidis 
 
Overall Incidence 
 
A total of 5 cases of invasive Neisseria meningitidis were reported to AIP in 2008 for an overall 
rate of 0.7/100,000.  The Alaska rates are slightly higher than the ABCs 2008 national projected 
rate of 0.3/100,000 [9].  There were no invasive N. meningitidis-related deaths in Alaska in 2008.   
  
Seasonality 
 
One N. meningitidis case occurred in each month of April, June, July, August and October; no 
clusters of related cases were reported. 
 
Race 
 
In 2008, 80% of the cases occurred in non-Natives.  Age-adjusted rates were calculated for 
Alaska Natives and non-Natives.  The age-adjusted rate ratio of N. meningitidis disease for the 
non-Native population compared with the Alaska Native population in 2008 was 1.7. 
 
Table 14:  Invasive Neisseria meningitidis Cases by Race – Alaska, 2008 
Race 
Cases 
n (%) 
Age Adjusted 
Rate* % Male 
Deaths 
n (%) 
Alaska Native 1 (20%) 0.45 0 0 (0%) 
Non-Native 4 (80%) 0.75 75 0 (0%) 
Total 5  60 0 
*Cases per 100,000 per percent distribution of Alaska 2000 population 
 
Region 
 
Four cases of invasive N. meningitidis occurred in Anchorage and one case occurred in the 
Interior.   
 
Age 
 
Invasive N. meningitidis cases reported in 2008 ranged in age from 0.2 to 29.6 years old; the 
median age was 0.6 years.   
 
Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each 
patient’s individual medical record associated with the invasive bacterial illness.  In cases with 
multiple discharge diagnoses, the most serious diagnosis related to the N. meningitidis infection 
was recorded as the primary clinical presentation.  Four cases presented with meningitis and one 
with bacteremia; one case had a secondary clinical presentation of cellulitis. 
 
 Surveillance of Invasive Bacterial Disease in Alaska, 2008                                                    22         
N. meningitidis was isolated from cerebrospinal fluid in four of five (80%) cases in 2008.  One 
case was isolated from blood. 
 
Mortality 
 
There were no N. meningitidis-related deaths reported in Alaska in 2008.   
 
Serogroup 
 
Five invasive N. meningitidis cases in 2008 were serogrouped; three were serogroup B and two 
were serogroup Y. 
 
Table 15:  Summary of Invasive Neisseria Meningitidis Cases Characteristics, Alaska, 2008 
Sex 
Age 
(yrs) Race Residence 
Site of 
Isolation 
Clinical 
Presentation(s) Serogroup 
Associated 
Medical 
Conditions Survived 
M 0.2 Non-Native Anchorage CSF Meningitis B None Yes 
F 0.2 AK Native Other Blood Bacteremia Y None Yes 
M 0.6 Non-Native Anchorage CSF Meningitis, 
cellulitis Y None Yes 
M 1.4 Non-Native Anchorage CSF Meningitis B None Yes 
F 20.6 Non-Native Anchorage CSF Meningitis B None Yes 
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Invasive group A Streptococcus 
 
Overall Incidence 
 
A total of 38 cases of invasive group A Streptococcus (GAS) were reported to AIP in 2008.  The 
overall rate of invasive GAS disease in the state of Alaska was 5.6/100,000 persons per year.  
The Alaska rate is higher than the ABCs 2008 national projected rate of 3.9/100,000 [10].  In 
2008, there were 5 GAS-related deaths (emm types 1 (2 cases), 73, 108.1 and one unknown) for a 
case fatality ratio of 13.2%. 
 
Seasonality 
 
Cases of group A Streptococcus occurred throughout the year in 2008 with no apparent trends in 
seasonality. 
 
Race 
 
In 2008, 47% of invasive GAS cases in Alaska occurred in the Alaska Native population for an 
age-adjusted rate of 12.3/100,000 persons per year which was three and a half times higher than 
the non-Native age-adjusted rate of 3.5/100,000 persons per year.   
 
Table 16:  Invasive group A Streptococcus Cases by Race – Alaska, 2008 
Race 
Cases 
n (%) 
Age Adjusted 
Rate* % Male 
Deaths 
n (%) 
Alaska Native 17 (45%) 12.3 65 1 (6%) 
Non-Native 21 (55%) 3.5 71 4 (19%) 
Total 38  68 5 (13%) 
*Cases per 100,000 per percent distribution of Alaska 2000 population 
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Figure 15: Invasive group A Streptococcus, by 
Month of Culture - Alaska, 2008
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Region 
 
Twenty five (65.8%) of the 38 invasive group A Streptococcus cases in 2008 were reported in 
the Anchorage area, 6 cases in the YK Delta, 3 cases each in Southeast and Kotzebue, and one 
case in the Interior. 
 
Age 
 
Invasive group A Streptococcus cases reported in 2008 ranged in age from 2.4 months to 87.2 
years old; the median age was 51.6 years.  Highest rates of disease occurred in adults 65 and 
older (22.2/100,000).   
 
 
When stratified by race, the highest rates of invasive group A streptococcal disease occurred in 
Alaska Native adults 65 and older (75.3/100,000 persons per year).  The highest GAS disease 
rate in the non-Native population occurred in adults 65 and older (12.1/100,000 persons per 
year).   
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Figure 16: Invasive group A Streptococcus by Age 
Group - Alaska, 2008
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Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each 
patient’s individual medical record associated with the invasive bacterial illness.  In cases with 
multiple discharge diagnoses, the most serious diagnosis related to the GAS infection was 
recorded as the primary clinical presentation.  Table 17 shows the primary clinical presentations 
of invasive group A Streptococcus in Alaska for 2008.  Nine cases also presented with secondary 
diagnoses including endocarditis, cellulitis, osteomyelitis and bursitis. 
 
Group A Streptococcus was isolated from blood samples in 32 (84%) of 38 cases, five from joint 
fluid and one from a surgical sample. 
  
Table 17:  Primary Clinical Presentations of Invasive group A Streptococcus – Alaska, 2008 
Primary Presentation n (%) 
Cellulitis* 15 (39%) 
Pneumonia* 8 (21%) 
Bacteremia 7 (18%) 
Septic arthritis 2 (5%) 
Necrotizing fasciitis 2 (5%) 
Meningitis 1 (3%) 
Bursitis 1 (3%) 
Other 2 (5%) 
Total 38 
*with bacteremia 
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 Table 18:  Summary of Invasive group A Streptococcus Case Characteristics, Alaska, 2008 
Sex 
Age 
(yrs) Race Residence 
Site of 
Isolation Clinical Presentation(s) 
emm 
Type 
Associated Medical 
Conditions Survived 
M 0.2 Non-Native Anchorage Blood Bacteremia 9.00 None Yes 
M 0.6 AK Native Other Blood Cellulitis 82.00 None Yes 
M 1.2 AK Native Other Blood Bacteremia 82.00 None Yes 
F 6.1 AK Native Other Blood Cellulitis 12.00 None Yes 
M 18.5 AK Native Anchorage Blood Bacteremia 108.10 Chronic lung disease, diabetes Yes 
F 24 Non-Native Anchorage Blood Bacteremia, other 1.00 None No 
M 32.3 Non-Native Anchorage Blood Cellulitis  Smoking, diabetes Yes 
M 33 AK Native Anchorage Blood Cellulitis 58.00 Smoking, alcohol abuse Yes 
F 33 Non-Native Anchorage Blood Other 108.10 Smoking Yes 
F 35.9 Non-Native Other Blood Other 44.00 Chronic lung disease Yes 
F 41.2 Non-Native Anchorage Blood Cellulitis 108.10 Diabetes Yes 
F 41.8 Non-Native Anchorage Blood Meningitis, endocarditis, pneumonia 73.00 
Smoking, chronic lung 
disease, alcohol abuse, 
diabetes 
No 
M 47 AK Native Anchorage Blood Cellulitis 108.10 Smoking, alcohol abuse Yes 
M 47.3 Non-Native Anchorage Blood Cellulitis 108.10 Smoking, alcohol abuse, diabetes Yes 
M 49 AK Native Other Joint fluid Septic arthritis, cellulitis 82.00 Smoking Yes 
F 49.1 Non-Native Anchorage Joint fluid Cellulitis, bursitis 9.20 Chronic lung disease, diabetes Yes 
M 49.5 Non-Native Anchorage Joint fluid Cellulitis, bursitis  Smoking, chronic lung disease, alcohol abuse Yes 
M 49.7 Non-Native Anchorage Blood Pneumonia 1.00 Asplenia No 
M 51 Non-Native Anchorage Blood Pneumonia 82.00 Alcohol, immuno-
suppressive treatment Yes 
M 52.2 AK Native Anchorage Wound Necrotizing fasciitis  Smoking, chronic lung disease, alcohol abuse Yes 
F 54.4 AK Native Other Blood Pneumonia, cellulitis 1.00 Smoking, alcohol abuse, injection drug use Yes 
M 54.5 Non-Native Anchorage Blood Necrotizing fasciitis 108.10 Alcohol abuse No 
M 57.3 Non-Native Anchorage Blood Bacteremia 92.00 Smoking Yes 
M 58.6 Non-Native Anchorage Blood Cellulitis  Smoking, alcohol abuse, diabetes Yes 
F 59.8 AK Native Other Blood Bacteremia 44.00 Smoking Yes 
M 62 Non-Native Anchorage Blood Cellulitis 108.10 Diabetes Yes 
M 64.2 AK Native Anchorage Blood Cellulitis 92.00 Smoking, alcohol abuse Yes 
M 68 Non-Native Anchorage Blood Cellulitis  None Yes 
M 69.4 Non-Native Anchorage Blood Cellulitis, other 1.00 Chronic lung disease, diabetes Yes 
M 70.7 AK Native Other Joint fluid Bursitis  Unknown Yes 
M 71.7 AK Native Other Blood Pneumonia 1.00 None Yes 
M 72.6 Non-Native Anchorage Blood Bacteremia 1.00 None Yes 
F 74.2 AK Native Other Blood Cellulitis  None Yes 
M 76.8 Non-Native Anchorage Blood Pneumonia 28.00 None Yes 
F 81 AK Native Other Blood Pneumonia, 
osteomyelitis  Chronic lung disease No 
M 82.3 AK Native Other Joint fluid Septic arthritis, cellulitis  Diabetes Yes 
M 83.2 Non-Native Anchorage Blood Pneumonia 82.00 Chronic lung disease, diabetes Yes 
F 87.2 AK Native Other Blood Pneumonia 49.00 None Yes 
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Invasive group B Streptococcus 
 
Overall Incidence 
 
A total of 28 cases of invasive group B Streptococcus (GBS) were reported to AIP in 2008.  The 
overall rate of invasive GBS disease in the state of Alaska was 4.1/100,000 persons per year.  
The Alaska rate is lower than the ABCs 2008 national projected rate of 6.5/100,000 [11].  In 
2008, there was one GBS-related death for a case fatality ratio of 3.7% (outcome was unknown 
in 1 case). 
 
Seasonality 
 
Cases of group B Streptococcus occurred throughout the year with no apparent trends in 
seasonality.   
 
 
Race 
 
In 2008, 37% of invasive group B Streptococcus cases in Alaska occurred in the Alaska Native 
population; the age-adjusted rate was 5.7/100,000 persons per year which is more than one and 
half times the non-Native age-adjusted rate of 3.1/100,000 persons per year.  
 
Table 19:  Invasive group B Streptococcus Cases by Race – Alaska, 2008 
Race 
Cases 
n (%) 
Age Adjusted 
Rate* % Male 
Deaths 
n (%) 
Alaska Native 8 (29) 5.7 87.5 0 (0) 
Non-Native 20 (71)‡ 3.1 60 1 (5.3) 
Total 28   68 1 (3.7) 
*Cases per 100,000 per percent distribution of Alaska 2000 population 
‡Includes one case for which race was unknown 
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Figure 18: Invasive group B Streptococcus, by 
Month of Culture - Alaska, 2008
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Region 
 
In 2008, 20 (71%) of the 28 reported GBS cases occurred in Anchorage; four cases were 
reported in the Interior, three cases in Southeast Alaska, and one in the YK Delta.   
 
Age 
 
Invasive group B Streptococcus cases reported in 2008 ranged in age from newborn to 104.6 
years old; the median age was 60.3 years.  Highest rates of disease occurred in adults 65 years 
and older (24.3/100,000 persons per year).   
 
 
 
 
 
When stratified by race, the highest rates of disease occurred in AK Native adults 65 years of age 
and older (37.6/100,000 persons per year).  There was one case of early-onset disease (less than 
7 days old) for a rate of 0.1/1,000 births.   
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Figure 19: Invasive group B Streptococcus by Age 
Group - Alaska, 2008
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Clinical Presentation 
 
The primary clinical presentation was determined by a review of the discharge diagnoses in each 
patient’s individual medical record associated with the invasive bacterial illness.  In cases with 
multiple discharge diagnoses, the most serious diagnosis related to the GBS infection was 
recorded as the primary clinical presentation.  In 2008, the most common clinical presentation 
was bacteremia which occurred in 14 cases (50%).   
 
Group B Streptococcus was isolated from blood in 22 (79%) of 28 cases in 2008; three cases 
were isolated from joint fluid and one case each was isolated from peritoneal fluid, a surgical 
specimen and an unspecified non-sterile site.   
 
Table 20:  Primary Clinical Presentations of Invasive group B Streptococcus – Alaska, 2008 
 
*with bacteremia 
 
Antibiotic Resistance 
 
Susceptibility testing was performed on 25 GBS isolates received in 2008.  Results of the testing 
are presented in the following table. 
 
Table 21:  Antibiotic Resistance in Invasive group B Streptococcus Isolates – Alaska, 2008 
Antibiotic Susceptible Intermediate Resistant I + R Total Tested 
Penicillin 25 (100%) 0 (0%) 0 (0%) 0 (0%) 25 
Ceftriaxone 25 (100%) 0 (0%) 0 (0%) 0 (0%) 25 
Erythromycin 11 (44%) 0 (0%) 14 (54%) 14 (54%) 25 
Tetracycline 1 (4%) 0 (0%) 24 (96%) 24 (96%) 25 
Levofloxacin 25 (100%) 0 (0%) 0 (0%) 0 (0%) 25 
Clindamycin 19 (76%) 0 (0%) 6 (24%) 6 (24%) 25 
Vancomycin 25 (100%) 0 (0%) 0 (0%) 0 (0%) 25 
 
All isolates tested were susceptible to penicillin, ceftriaxone, vancomycin and levofloxacin.  
Resistance to tetracycline, erythromycin and clindamycin was seen in 96%, 54% and 24%, 
respectively, of isolates tested.  An isolate from the one early onset case was susceptible to all 
antibiotics tested.
Primary Presentation n (%) 
Bacteremia 14 (50) 
Septic arthritis  5 (18) 
Cellulitis* 3 (11) 
Pneumonia* 2 (7) 
Osteomyelitis 1 (3.5) 
Meningitis 1 (3.5) 
Peritonitis 1 (3.5) 
Other 1 (3.5) 
Total 28 
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Table 21:  Summary of Invasive group B Streptococcus Case Characteristics, Alaska, 2008 
Sex Age (yrs) Race Residence 
Site of 
Isolation 
Clinical 
Presentation(s) 
Associated Medical 
Conditions Survived 
M Newborn AK Native Other Blood Bacteremia None Yes 
M 11 days Unknown Other Blood Bacteremia None Yes 
M 0.1 Non-Native Other Blood Bacteremia None Yes 
M 0.2 AK Native Anchorage Blood Bacteremia None Yes 
M 20.6 AK Native Other Blood Bacteremia Immunosuppressive treatment Yes 
F 25.3 Non-Native Anchorage Blood Osteomyelitis Diabetes No 
F 32.5 AK Native Anchorage Peritoneal fluid 
Peritonitis, 
endometritis Chronic lung disease Yes 
M 42.7 Non-Native Anchorage Blood Cellulitis Diabetes Yes 
M 48.1 AK Native Anchorage Blood Bacteremia None Yes 
M 50.1 Non-Native Anchorage Joint fluid Septic arthritis Smoking, alcohol abuse Yes 
F 50.6 Non-Native Anchorage Non-
sterile Cellulitis None Yes 
F 52 Non-Native Anchorage Blood Cellulitis Diabetes Yes 
M 54.7 Non-Native Other Joint fluid Septic arthritis Diabetes Yes 
M 59 Non-Native Anchorage Blood Cellulitis None Yes 
M 61.6 Non-Native Anchorage Joint fluid Septic arthritis Unknown Yes 
M 62.4 Non-Native Other Blood Bacteremia None Yes 
M 75.1 AK Native Anchorage Blood Bacteremia Chronic lung disease, 
alcohol abuse, diabetes Yes 
F 75.2 Non-Native Anchorage Blood Meningitis Diabetes Yes 
M 75.4 Non-Native Anchorage Blood Bacteremia None Yes 
M 75.7 Non-Native Anchorage Blood Bacteremia Diabetes Yes 
M 76.1 AK Native Other Blood Pneumonia Diabetes Yes 
F 76.5 Non-Native Anchorage Blood Septic arthritis Immunosuppressive treatment Yes 
M 76.6 Non-Native Anchorage Blood Bacteremia Smoking, chronic lung disease Yes 
F 76.7 Non-Native Anchorage Blood Bacteremia Chronic lung disease Yes 
M 86.6 Non-Native Anchorage Blood Pneumonia, cellulitis Chronic lung disease Yes 
F 92.1 Non-Native Anchorage Blood Bacteremia None Yes 
F 95 Non-Native Anchorage Blood Septic arthritis None Yes 
M 104.6 AK Native Other Surgical 
specimen Other Chronic lung disease Yes 
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Appendix 
 
MIC Interpretive Standards Definitions:  
 
CLSI [5] provides recommended interpretive categories for various Minimum Inhibitory 
Concentration values (cut points) for each organism/antibiotic combination which are defined as 
follows: 
 
 1.  Susceptible (S):   
 
The “susceptible” category implies that isolates are inhibited by the usually achievable 
concentrations of antimicrobial agent when the recommended dosage is used for the site of 
infection. 
 
2.  Intermediate (I):   
 
The “intermediate” category includes isolates with antimicrobial agent MICs that approach 
usually attainable blood and tissue levels and for which response rates may be lower than for 
susceptible isolates.  The “intermediate” category implies clinical efficacy applicability in body 
sites where the drugs are physiologically concentrated (e.g., quinolones and β-lactams in urine) 
or when a higher dosage of a drug can be used (e.g., β-lactams).  The “intermediate” category 
also includes a buffer zone which should prevent small, uncontrolled technical factors from 
causing major discrepancies in interpretations, especially for drugs with narrow 
pharmacotoxicity margins. 
 
3.  Resistant (R):   
 
Resistant strains are not inhibited by the usually achievable concentrations of the agent with 
normal dosage schedules, and/or that demonstrate MICs or zone diameters that fall in the range 
where specific microbial resistance mechanisms are likely (e.g., β-lactamases) are likely,  and 
clinical efficacy of the agent against the isolate has not been reliably shown in treatment studies.  
 
 
